BACKGROUND: @entity900 -based combinations are considered to be the standard treatment for advanced @entity1606 ( @entity1606 ) of the urothelium. Many of the @entity1 are elderly with @entity66 or @entity8 . We studied the tolerance and activity of the @entity136 / @entity3003 combination as a therapeutic alternative. METHODS: @entity1 with locally advanced or metastatic @entity1606 of the urothelium were treated with @entity136 1000 mg/m(2) on Days 1 and 8 and @entity3003 area under the concentration-time curve 5 on Day 1 every 21 days. @entity1 with creatinine clearance of 30 mL/min or above and Karnofsky performance status (KPS) scores 60 or above were enrolled. RESULTS: A total of 227 cycles were administered to 41 @entity1 , with an average of 5.5 cycles per @entity1 (range, 1-8 cycles). @entity1011 clearance was below 60 mL/min in 54% of @entity1 , KPS was 70 or below in 37% of @entity1 , and 37% of @entity1 were 70 years old or older. @entity1503 was mainly Grade 3/4 @entity1398 in 63%, Grade 3/4 @entity882 in 32%, and Grade 3/4 @entity417 in 54% of @entity1 . There were only three episodes of @entity1398 and one @entity204 from @entity1398 . Nonhematologic @entity137 was mild, with @entity1395 as the most frequently reported event. We obtained 6 complete and 17 partial responses, for an overall response rate of 56.1% (95% confidence interval [CI], 40.6-71.6%). Progression-free survival was 7.2 months (95% CI, 5.7-8.5) and median survival was 10.1 months (95% CI, 8.8-12.2). CONCLUSIONS: The combination of @entity136 plus @entity3003 achieves a similar result to doublets using @entity900 . It has an acceptable @entity137 profile and enables @entity1 with @entity8 and/or poor performance status and elderly @entity1 to be treated.

@entity136 and XXXX in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.

@entity1 :: ('9606', 'Species') :: ['patient', 'Patients', 'patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['impaired renal function'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity66 :: ('MESH:D004194', 'Disease') :: ['concomitant diseases'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin'] @entity1395 :: ('MESH:D001247', 'Disease') :: ['asthenia'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['Hematologic toxicity'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'neutropenic sepsis', 'febrile neutropenia'] @entity1606 :: ('MESH:D002295', 'Disease') :: ['transitional cell carcinoma', 'TCC'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['Creatinine'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']
